复宏汉霖拉升大涨超15%创阶段新高,HLX22治疗领域再度拓宽至乳腺癌疾病领域

格隆汇
22 Apr

复宏汉霖(2696.HK)盘中逆势拉升大涨超15%报39.2港元,股价创2021年7月以来新高。 消息面上,复宏汉霖近日宣布,公司创新型抗HER2单抗HLX22单抗注射液联合德曲妥珠单抗治疗HER2低表达HR阳性的局部晚期或转移性乳腺癌的II期临床研究(HLX22-BC201)于中国境内完成首例患者给药。继HER2阳性胃癌之后,HLX22的治疗领域再度拓宽至乳腺癌疾病领域,有望为更多肿瘤患者带来新...

Source Link

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10